Hematology/oncology expert, John P. Leonard, MD, describes the rationale for treating an elderly patient with relapsed/refractory follicular lymphoma with a PI3K inhibitor in the third-line setting.
EP. 1: Case Overview: Elderly Woman With Relapsed/Refractory FL
March 17th 2021Prior to discussing treatment options for a 71-year-old woman with relapsed/refractory follicular lymphoma, John P. Leonard, MD, of Weill Cornell Medicine and NewYork-Presbyterian Hospital, sets the stage with an overview of the patient’s case.
Watch
EP. 6: PI3K Inhibitors for Relapsed/Refractory FL: Safety & Efficacy
March 17th 2021John P. Leonard, MD, of Weill Cornell Medicine and NewYork-Presbyterian Hospital, comments on the safety and efficacy data for PI3K inhibitors for relapsed/refractory follicular lymphoma treatment and shares advice on best practices for monitoring patients on therapy and managing any treatment-related adverse events.
Watch